This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Ceramide AP
- DrugBank Accession Number
- DB14705
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Ceramide AP (DB14705)
- Weight
- Average: 599.982
Monoisotopic: 599.548874455 - Chemical Formula
- C36H73NO5
- Synonyms
- Biomide 6
- Ceramide 6
- Ceramide 6 II
- Ceramide VI
- Cytomide VI
- N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine
- N-(2-hydroxyoctadecanoyl)-4R-hydroxysphinganine
- N-(2-hydroxyoctadecanoyl)-hydroxysphinganine
- N-(2-hydroxyoctadecanoyl)phytoceramide
- N-(2-hydroxyoctadecanoyl)phytosphingosine
- N-2-hydroxystearoyl-phytosphingosine
- PHC-C 18:0/18:0
- phytosphingosine-2-hydroxy-18:0
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Liquid Ceramide AP (4.5 mg/30mg) + Avocado (9 mg/30mg) + Glycerin (6 mg/30mg) + Sodium hyaluronate (3 mg/30mg) Liquid Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- F1X8L2B00J
- CAS number
- 212070-45-6
- InChI Key
- BBAFBDLICMHBNU-MFZOPHKMSA-N
- InChI
- InChI=1S/C36H73NO5/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-34(40)36(42)37-32(31-38)35(41)33(39)29-27-25-23-21-19-16-14-12-10-8-6-4-2/h32-35,38-41H,3-31H2,1-2H3,(H,37,42)/t32-,33+,34?,35-/m0/s1
- IUPAC Name
- 2-hydroxy-N-[(2S,3S,4R)-1,3,4-trihydroxyoctadecan-2-yl]octadecanamide
- SMILES
- CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Cutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000253 mg/mL ALOGPS logP 8.36 ALOGPS logP 10.01 Chemaxon logS -6.4 ALOGPS pKa (Strongest Acidic) 12.7 Chemaxon pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 110.02 Å2 Chemaxon Rotatable Bond Count 33 Chemaxon Refractivity 176.87 m3·mol-1 Chemaxon Polarizability 80.27 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 24, 2018 17:24 / Updated at June 12, 2020 16:53